2Seventy Bio Inc (NASDAQ:TSVT) — Market Cap & Net Worth
Market Cap & Net Worth: 2Seventy Bio Inc (TSVT)
2Seventy Bio Inc (NASDAQ:TSVT) has a market capitalization of $266.14 Million ($266.14 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15447 globally and #3484 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2Seventy Bio Inc's stock price $5.00 by its total outstanding shares 53228300 (53.23 Million). Analyse 2Seventy Bio Inc cash flow conversion to see how efficiently the company converts income to cash.
2Seventy Bio Inc Market Cap History: 2021 to 2025
2Seventy Bio Inc's market capitalization history from 2021 to 2025. Data shows change from $1.36 Billion to $266.14 Million (-24.82% CAGR).
Index Memberships
2Seventy Bio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #415 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1483 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.02% | #218 of 263 |
Weight: 2Seventy Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
2Seventy Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2Seventy Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.13x
2Seventy Bio Inc's market cap is 4.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.36 Billion | $54.52 Million | -$292.21 Million | 25.02x | N/A |
| 2022 | $498.75 Million | $91.50 Million | -$254.14 Million | 5.45x | N/A |
| 2023 | $227.28 Million | $100.39 Million | -$217.57 Million | 2.26x | N/A |
| 2024 | $156.49 Million | $37.86 Million | -$57.25 Million | 4.13x | N/A |
Competitor Companies of TSVT by Market Capitalization
Companies near 2Seventy Bio Inc in the global market cap rankings as of May 2, 2026.
Key companies related to 2Seventy Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
2Seventy Bio Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, 2Seventy Bio Inc's market cap moved from $1.36 Billion to $ 266.14 Million, with a yearly change of -24.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $266.14 Million | +70.07% |
| 2024 | $156.49 Million | -31.15% |
| 2023 | $227.28 Million | -54.43% |
| 2022 | $498.75 Million | -63.44% |
| 2021 | $1.36 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of 2Seventy Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $266.14 Million USD |
| MoneyControl | $266.14 Million USD |
| MarketWatch | $266.14 Million USD |
| marketcap.company | $266.14 Million USD |
| Reuters | $266.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more